Abstract

Artificial intelligence applications in inflammatory bowel disease: Emerging technologies and future directions

World J Gastroenterol. 2021 May 7;27(17):1920-1935. doi: 10.3748/wjg.v27.i17.1920.

John Gubatan 1, Steven Levitte 2, Akshar Patel 2, Tatiana Balabanis 2, Mike T Wei 2, Sidhartha R Sinha 2

 
     

Author information

  • 1Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Redwood City, CA 94063, United States. jgubatan@stanford.edu.
  • 2Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Redwood City, CA 94063, United States.

Abstract

Inflammatory bowel disease (IBD) is a complex and multifaceted disorder of the gastrointestinal tract that is increasing in incidence worldwide and associated with significant morbidity. The rapid accumulation of large datasets from electronic health records, high-definition multi-omics (including genomics, proteomics, transcriptomics, and metagenomics), and imaging modalities (endoscopy and endomicroscopy) have provided powerful tools to unravel novel mechanistic insights and help address unmet clinical needs in IBD. Although the application of artificial intelligence (AI) methods has facilitated the analysis, integration, and interpretation of large datasets in IBD, significant heterogeneity in AI methods, datasets, and clinical outcomes and the need for unbiased prospective validations studies are current barriers to incorporation of AI into clinical practice. The purpose of this review is to summarize the most recent advances in the application of AI and machine learning technologies in the diagnosis and risk prediction, assessment of disease severity, and prediction of clinical outcomes in patients with IBD.

 

 

© Copyright 2013-2021 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.